Contemporary Practice and Considerations for Real‐World Data Source Identification and Feasibility Assessment
Existing guidelines are used extensively by researchers, but key criteria for RWD identification and feasibility assessment are not reflected consistently and challenges remain. Recommendations have been made reflecting study findings.
Authors
- Tzuyung D. Kou (ORCID: https://orcid.org/0000-0003-3274-770X)
- Marta Korjagina
- Lina Titievsky (ORCID: https://orcid.org/0000-0002-1801-1168)
- Sheuli Porkess (ORCID: https://orcid.org/0000-0002-7915-8163)
- Deborah Layton (ORCID: https://orcid.org/0000-0002-8557-1376)
- Nicholas Everage (ORCID: https://orcid.org/0000-0001-7216-7836)
- Dony Patel (ORCID: https://orcid.org/0000-0002-9153-4176)
- Sonia Guleria
- Susanna Flaherty
Institutions
- Biogen (United States) (US)
- University of Hertfordshire (GB)
- IQVIA (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- Daiichi Sankyo (United States) (US)
- 21c Consultancy (United Kingdom) (GB)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1002/pds.5862
- Citations
- 4
- Primary Topic
- Scientific Computing and Data Management
- Type
- article
- Field-Weighted Citation Impact
- 4.20
Funders
- International Society for Pharmacoepidemiology